Volume 377, Issue 9784, Pages 2181-2192 (June 2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo- controlled trial  Prof Colin Baigent, FRCP, Martin J Landray, FRCP, Christina Reith, MRCP, Jonathan Emberson, PhD, David C Wheeler, FRCP, Charles Tomson, DM, Prof Christoph Wanner, MD, Vera Krane, MD, Prof Alan Cass, FRACP, Prof Jonathan Craig, PhD, Prof Bruce Neal, FRCP, Lixin Jiang, MD, Lai Seong Hooi, FRCP, Prof Adeera Levin, FRCPC, Prof Lawrence Agodoa, FACP, Prof Mike Gaziano, MD, Prof Bertram Kasiske, FACP, Prof Robert Walker, FRACP, Prof Ziad A Massy, MD, Prof Bo Feldt-Rasmussen, MD, Udom Krairittichai, MD, Vuddidhej Ophascharoensuk, MD, Prof Bengt Fellström, MD, Hallvard Holdaas, MD, Prof Vladimir Tesar, FASN, Prof Andrzej Wiecek, FRCP, Prof Diederick Grobbee, FESC, Prof Dick de Zeeuw, MD, Prof Carola Grönhagen-Riska, MD, Tanaji Dasgupta, MRCP, David Lewis, MRCP, William Herrington, MRCP, Marion Mafham, MD, William Majoni, FRACP, Karl Wallendszus, MSc, Prof Richard Grimm, MD, Prof Terje Pedersen, MD, Jonathan Tobert, PhD, Prof Jane Armitage, FRCP, Alex Baxter, BA, Christopher Bray, PhD, Yiping Chen, DPhil, Prof Zhengming Chen, DPhil, Michael Hill, DPhil, Carol Knott, MSc, Sarah Parish, DPhil, David Simpson, Prof Peter Sleight, MD, Alan Young, DPhil, Prof Rory Collins, FMedSci  The Lancet  Volume 377, Issue 9784, Pages 2181-2192 (June 2011) DOI: 10.1016/S0140-6736(11)60739-3 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events Numbers remaining at risk of a first major atherosclerotic event at the beginning of each year are shown for both treatment groups. The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Major atherosclerotic events subdivided by type MI=myocardial infarction. CHD=coronary heart disease. The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Major atherosclerotic events by baseline characteristics χ2 tests on 1 degree of freedom are shown for heterogeneity between rate ratios within dichotomous categories and for trend within other categories. BP=blood pressure. MDRD=Modified Diet in Renal Disease formula.17 GFR=glomerular filtration rate. The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 5 Cause-specific and overall mortality CHD=coronary heart disease. The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 6 Effects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients Data from the Cholesterol Treatment Trialists' Collaboration.5 χ2 tests are shown for heterogeneity between rate ratios for each outcome in the four trials (4D,19 ALERT,21 AURORA,20 and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol. The Lancet 2011 377, 2181-2192DOI: (10.1016/S0140-6736(11)60739-3) Copyright © 2011 Elsevier Ltd Terms and Conditions